Market News AIOpen the app

Vanda Pharmaceuticals says its new anxiety drug didn’t meet key goals in testing.

TrialRead the original at Benzinga
Bad for VNDA

Vanda's VQW-765 Phase 3 study missed its main goal in women and its second goal across all participants. Earlier Phase 2 participants reported lower stress, but the later study did not confirm that result, weakening the drug's prospects.

VNDA · Vanda Pharmaceuticals Inc.

AI read · Bad for VNDA

The AI's read

That leaves Vanda without evidence that VQW-765 can ease acute social anxiety. The earlier Phase 2 study had reported lower stress scores, but the Phase 3 study did not confirm that result. The missed second goal across men and women adds to the setback.

Get alerts for VNDA

Follow Vanda Pharmaceuticals Inc. (VNDA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for VNDA
Free on the App Store and Google Play, or on the web.